PromiCell is leading the fight against cancer through cutting-edge CAR T and TCR T therapies. Leveraging innovative technology and strategic collaborations, we are developing potentially curative solutions to transform lives.
PromiCell is a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients. Building on our experience in rapidly translating promising academic research into clinical applications, we strive to move innovative therapies towards the clinic.
Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. CARs are engineered proteins that modify T cells to recognize and eliminate cancer cells. We believe current therapies face limitations, including a lack of durability, safety concerns, and unreliable supply.
Our therapies are optimized for superior in vivo functionality, generating a ‘3-dimensional’ anti-tumor response to improve the depth, durability, and breadth of their impact. This expands their utility across both solid and hematologic tumors.
Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients.
PromiCell’s advanced CAR T and TCR platforms are designed to overcome the toughest challenges in oncology. By integrating cutting-edge genetic engineering, our therapies address tumor resistance, improve anti-tumor responses, and enhance durability.
With innovations like IL-18 cytokine armoring and fully human constructs, our solutions offer unmatched precision and safety, targeting both antigen-positive and antigen-negative tumors while providing lasting outcomes for patients.
PromiCell’s therapies are backed by robust preclinical data that demonstrate their transformative potential. Our CAR T and TCR therapies have achieved complete tumor clearance in prostate cancer and Ewing Sarcoma models within weeks.
With FDA-allowed Phase 1 trials already underway, our pipeline is supported by extensive safety and efficacy studies, laying a strong foundation for clinical success and delivering hope to patients that are difficult to treat.
PromiCell’s exclusive collaborations with Fred Hutchinson Cancer Research Center (FH) and Memorial Sloan Kettering Cancer Center (MSK) provide access to world-class expertise and infrastructure.
These partnerships enable us to accelerate breakthroughs in targeting critical unmet needs, including prostate cancer, AML, and Ewing Sarcoma. Together, we are driving innovation to bring next-generation cellular therapies to patients who need them most.
We help organizations in banking, insurance, government, healthcare, and beyond, scale their platforms and take their applications to the next level. Our low code powered in-house tools offer our customers the added advantage of extreme agility ensuring they are always on top of their competitors.
PromiCell, established in Delaware in October 2022, is a clinical-stage biotechnology company at the forefront of developing transformative cell therapies to combat cancer. Since launching operations in April 2023, we have raised $12 million from four family offices, entered into exclusive license agreements with renowned cancer research centers, and initiated Phase 1 clinical trials on groundbreaking CAR T-cell therapies.
At PromiCell, our mission is to transform cancer care by advancing groundbreaking CAR T and TCR therapies. Through innovation, collaboration with world-class institutions, and a relentless focus on patients, we aim to deliver life-changing solutions that address critical gaps in oncology and provide new hope for those fighting cancer.
To build a fully integrated cell therapy company with a focus on delivering transformative solutions for solid and hematologic cancers. With multiple clinical programs and scalable platforms, PromiCell is poised to become a leader in delivering the next wave of novel cancer treatments.
PromiCell is offering an exciting opportunity for investors to join our mission. With a target of raising up to $75 million, funds will primarily support preclinical and clinical trials, manufacturing, and strategic asset acquisitions. Early investors benefit from the potential for high-impact returns, supported by our scientifically validated platform and robust pipeline.
New prostate cancer cases targeted annually by our CAR T therapies.
Prostate cancer patients expressing STEAP1, the focus of our lead CAR T therapy.
Clinical Trials ongoing.
5 Clinical Trials Planned
for 2026.
Exclusively Licensed from Fred Hutchinson Cancer Center, targeting metastatic castration-resistant prostate cancer (mCRPC)
Demonstrated robust tumor response in preclinical studies
Phase 1 trial enrolling patients at Fred Hutchinson Cancer Center, and supported by NExT (NCI Experimental Therapeutics Program)
Exclusively Licensed from Fred Hutchinson Cancer Center, targeting metastatic castration-resistant prostate cancer (mCRPC)
Demonstrated complete tumor eradication in preclinical studies
IND application expected by late 2025, with clinical trial opening expected in 2026
Exclusively Licensed from Fred Hutchinson Cancer Center, targeting metastatic castration-resistant prostate cancer (mCRPC)
Combines STEAP1 targeting with IL-18 cytokine to generate a pro-inflammatory immune environment to deliver deeper and more reliable tumor control
IND application expected by late 2025, with clinical trial opening expected in 2026
Exclusively Licensed Licensed from Fred Hutchinson Cancer Center, targeting leukemia relapse after allogeneic bone marrow transplantation
First-in-human studies showed safety and signal of response in 4 out of 9 patients (NCT03326921)
Phase 1 trial completion expected in 2025 with plan to transfer to phase 2 with updated manufacturing and clinical protocol, addressing a large patient population across different leukemia types
Exclusively Licensed from Memorial Sloan Kettering Cancer Center (MSK), targeting relapsed/refractory acute myeloid leukemia
Demonstrated markedly superior potency over current clinically validated best-in-class CD33-specific CAR T therapies in preclinical models
IND-enabling studies are ongoing with IND filing and clinical trial opening expected in Q4 2025/Q1 2026
We are incorporating advanced, automated cell therapy manufacturing technology from Xcellbio in San Francisco. This platform enables GMP-compliant manufacturing in hypoxic (low-oxygen) environments, mimicking the solid tumor microenvironment. Preliminary data indicate:
• Enhanced biological functionality of CAR T cells.
• Longer and improved tumor-killing capabilities.
PromiCell will be among the first clinical partners to adopt Xcellbio’s platform, enhancing the quality, cost-efficiency, and therapeutic potential of cell therapies, particularly for solid tumors.
Employees
Fortune 500 Clients
Life Time Value per Client
Revenue in 2021
Founded in October 2022, marking the beginning of our mission to outsmart cancer with next-generation T-cell therapies.
Signed a pivotal licensing agreement with Fred Hutch for the development of STEAP1, STEAP1 IL-18, and HA-1 therapies.
Secured $10 million in capital to drive early-stage development.
Successfully advanced three assets from discovery to preclinical phase, solidifying our pipeline.
Received FDA’s Safe to Proceed in April and initiated the first clinical trial for STEAP1 CAR T in Q4 2024, marking a significant milestone. Prepared to launch a second clinical trial in the first half of 2025, to be completed by the end of the year. Entered a key licensing agreement with Memorial Sloan Kettering (MSK) for the development of CD33 CAR T therapy. Planning to submit three Initial New Drug Applications (IND) to the FDA within 2025 and subject to Phase 1 trial results launch two Phase 2 trials within 2026.
Company founded in October 2022$4.0 MM Raised
Fred Hutch Licensing Agreement$80MM Valuation
MSK Licensing Agreement$80MM Valuation
Warrant Exercises (Oct & Nov 2023)$6MM Raised
Final Warrant Exercise (Oct 2024)$2MM Raised
Raising Growth Capital (2025)Up to $75MM
2026IPO on NASDAQ
• Exclusive licensing agreements for STEAP1 CAR T, IL-18 armored CAR T, and HA-1 TCR T assets.
• Leverages Fred Hutch’s world-class translational research and clinical capabilities to advance innovative therapies.
• Strategic partnership for the development of CD33 CAR T for Acute Myeloid Leukemia.
• Access to MSK’s leading-edge immunotherapy expertise and advanced manufacturing capabilities.
Our lead program targets metastatic castration-resistant prostate cancer (mCRPC) with a novel IL-18 armored CAR T cell therapy. Phase 1 trials are ongoing, supported by robust preclinical data demonstrating complete tumor responses within 5 weeks.
This therapy addresses leukemia relapse following bone marrow transplantation. With proven safety and efficacy in first-in-human trials, Phase 1 clinical trials are set to begin in early 2025.
A cutting-edge therapy for AML, demonstrating superior potency in preclinical models. IND submission is anticipated by Q4 2025, with clinical trials planned shortly thereafter.
We help organizations in banking, insurance, government, healthcare, and beyond, scale their platforms and take their applications to the next level. Our low code powered in-house tools offer our customers the added advantage of extreme agility ensuring they are always on top of their competitors.
Scalable Manufacturing: PromiCell integrates automated, GMP-compliant manufacturing platforms, reducing costs and ensuring the consistent production of high-quality cell therapies.
Strategic Partnerships: Collaborations with Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering (MSK) provide access to cutting-edge research, world-class infrastructure, and unparalleled clinical expertise. These partnerships de-risk novel proprietary terminologies, accelerating development and the path to market.
Advancing a Robust Pipeline: STEAP1 CAR T: Targeting metastatic castration-resistant prostate cancer, now in Phase 1 trials with preclinical data showing complete tumor response within 5 weeks.
HA-1 TCR T: Focused on leukemia relapse following bone marrow transplants, with first-in-human trials showing a sign of chemical response.
CD33 CAR T: Targeting at acute myeloid leukemia, demonstrating superior potency over current best in class CAR T therapies in preclinical models.
US trained neurosurgeon and biotech entrepreneur. Trained at Memorial and New York Presbyterian Hospitals. B.S. in Biomedical Engineering, and a Medical Degree from Boston University. Extensive research at Harvard, Tufts and Rockefeller.
Associate Professor, Division of Hematology / Oncology, UCLA. His lab is focused on developing cellular immunotherapy strategies for prostate and bladder cancer. John is a recipient of several young investigator awards, including the NIHDirector’s New Innovator Award, Prostate Cancer Foundation Young Investigator and Challenge Awards, and multiple awards from the Department of Defense.
Currently serving as a medical oncologist at Memorial Sloan Kettering who cares for patients with leukemia. Tony is a member of MSK’s Cellular Therapeutics Center. The Center is working to develop the next generation CAR T Cell Therapy. Completed residency at Cornell/ New York Presbyterian Hospital, and Oncology fellowship at MSKCC.
Managing Director, Seaborne Capital Advisors. 20+ years investment banking & corporate finance experience. Previously with Cantor Fitzgerald & Co and Jefferies & Company, Inc. in the United States. MBA in Finance, BentleyCollege, Waltham Massachusetts
More than 25 years of experience in M&As, private equity and venture capital investments, JVs, financings, capital markets transactions. Partner in BakerMcKenzie. Partner in Ropes & Gray. Corporate counsel for Hewlett-Packard Company for 5 years. Ranked by the Legal 500 US in the M&A/Corporate and Commercial category for M&A and Media, Technology and Telecoms. Named "Stand-Out Lawyer" by Thomson Reuters, 2022.
Raised to date
Valuation
Per Share
Rights
The company is conducting an offering of shares of Class A common stock initially to accredited investors only pursuant to Rule 506(c) of Regulation D (Reg D506(c)). We have also confidentially submitted to the Securities and Exchange Commission (SEC) under Form 1-A an Offering Statement for review. Once the review process is complete, we will also initiate an offering of shares of Class A common stock to the public pursuant to Regulation A+ (“Reg A+”).
We are currently offering up to 15 million shares of Class A Common Stock under Reg D506(c) to accredited investors. Once our Offering Statement is qualified by the SEC we will offer up to 15 million shares of Class A Common Stock to the public pursuant to Reg A+. As of December 31, 2024, the Company has the following outstanding shares and options:
● 18,416,100 shares of Class A Common Stock and;
● 100,000 shares of Class B Common Stock;
● 8,000,000 shares of Preferred Stock designated as Series A Preferred Stock with a conversion ratio of 1:1 to shares of Class A Common Stock; and
● 2,170,000 stock options which entitle the holders to purchase 2,170,000 shares of Class A Common Stock over the 10 years following their respective issuance date.
Our amended and restated certificate of incorporation authorizes the issuance of a maximum of 100,000,000 shares of Common Stock, consisting of 99,900,000 shares of Class A Common Stock and 100,000 shares of Class B Common Stock, plus up to 14,000,000 shares of Preferred Stock.
The company is conducting an offering of securities pursuant to Reg D506(c) and is planning to commence a concurrent offering of securities pursuant to Reg A+. The Reg D506(c) offering will likely include direct negotiations with institutional and strategic investors seeking investment terms that are more advantageous than the terms in the Reg A+ offering. Examples of more advantageous terms could include a price per share lower than the price per share in the Reg A+ offering, additional information rights or preemptive rights, liquidation preferences, or even a right to nominate a director to our Board. Sales under Reg D506(c) offering may be done concurrently with sales under Reg A+ offering. Sales under Reg D506(c) offering require verification of accredited investor status and are sales of restricted securities while sales under Reg A+ offering are sales of freely tradeable unrestricted securities to the public.
Both offerings are done on a “best efforts” basis with no offering minimum so the company will have access to any funds tendered.
Individual investors, family offices, our executives, board members own our outstanding shares. In particular our executive officers, directors and certain principal stockholders beneficially owned approximately 46.40% of our outstanding Common Stock as of December 31, 2024. In addition, our Chairman, Chief Executive Officer and Director holds all our outstanding Class B Shares of Common Stock entitled to 1,000 votes for each share on all matters submitted to a vote of stockholders, subject to a maximum voting limit of not more than 49% of all the eligible votes. Class A Shares of Common Stock are entitled to 1 such vote for each share.
Reg A+ is a framework for capital-raising that was created under the JOBS Act and subsequently implemented by the Obama administration in 2015. The framework is meant to provide a more cost-effective means of raising capital for companies wishing to avoid the hefty expenses, resources, and reporting obligations typically required under the Exchange Act when selling public securities.
While Reg A+ offerings can function similarly to a traditional IPO, they allow for greater flexibility when it comes to gauging public interest in the company’s securities and the types of investors allowed to purchase those securities. As of March 15, 2021, Reg A+ rules allow companies to raise up to $75 million in a 12-month period.
Regulation D is a Securities and Exchange Commission (SEC) regulation governing private placement exemptions. Reg D offerings are advantageous to private companies that meet the requirements because funding can be obtained faster and at a lower cost than with a public offering. The regulation allows capital to be raised through the sale of securities without the need to register those securities with the SEC. However, many other state and federal regulatory requirements still apply. Rule 506(c) of Regulation D permits issuers to broadly solicit and generally advertise an offering, provided that:
• all purchasers in the offering are accredited investors
• the issuer takes reasonable steps to verify purchasers’ accredited investor status and
• certain other conditions in Regulation D are satisfied
Purchasers in a Rule 506(c) offering receive “restricted securities.” A company is required to file a notice with the Commission on Form D within 15 days after the first sale of securities in the offering. Although the Securities Act provides a federal preemption from state registration and qualification under Rule 506(c), the states still have authority to require notice filings and collect state fees. Rule 506(c) offerings are subject to “bad actor” disqualification provisions.
Companies that wish to offer securities pursuant to Reg A+ must file an offering statement with the SEC’s Division of Corporation Finance via Form 1-A. Initially the offering statement may be submitted confidentially for review to the SEC. Following the review process the offering statement is filed publicly with the SEC and is available at www.SEC.gov and must be qualified before the company can begin selling securities.
Yes, Dalmore Securities is acting as the broker dealer of record. A broker-dealer provides a much more hands-on facilitation of the sale of securities and is legally held to higher standards of due diligence. A broker-dealer can offer investment advice, solicit the purchase of securities, compensate others for solicitation, and manage the securities themselves. However, broker-dealers’ fees can be quite expensive, which often leads them to reject capital raises below a certain price point.
Dalmore Technologies provides our online funding portals which are integrated with our investor landing page at www.investinpromicell.com. The funding portal allows potential investors to review our investment opportunity and purchase shares of Class A Common Stock.
Our Offering Statement includes audited financial statements for the fiscal year ending December 31, 2022, and 2023 as well as unaudited financial statements for the first nine months of 2024. We will be required to file annual audited financial statements under Form 1-K within 120 calendar days of the fiscal year ended on December 31st and unaudited semi-annual financial statements under Form 1-SA on an ongoing basis, as well as current event reports within four business days from the event under Form 1-U whenever certain changes to the business occur, such as:
1. fundamental changes in the business
2. bankruptcy or receivership
3. material modification to rights of security holders
4. changes in issuer’s certifying accountant
5. non-reliance on previously issued financial statements
6. changes in control of issuer
7. departure of certain officers
8. certain unregistered sales of equity securities of 10% or more of outstanding equity securities
The shares of Class A common Stock sold pursuant to Regulation A+ are not restricted under US securities laws and will become liquid upon issuance and are freely tradeable with no transfer restrictions. However, there is no obligation for the company to create a market for those shares.
The shares of Class A Common Stock to be sold pursuant Reg D506(c) will not be registered and hence, will be deemed to be “restricted securities” for purposes of the Securities laws. Rule 144, a regulation enforced by the SEC, sets the conditions for the sale or resale of restricted unregistered securities. It provides an exemption from registration requirements for the sale of securities through the public markets if a few specific conditions are met. These generally include a holding period of six months to a year and require that certain information about the Company is available. Purchasers of our shares of Class A Common Stock will have demand registration rights. They may, subject to certain conditions, require the company to register their shares for resale with the SEC in which case their shares will be freely tradable.
No, they will not. For companies not listed on the NYSE or NASDAQ, securities may be traded on over-the-counter markets such as the OTCQX or OTCQB or an electronic trading platform. There is no formal marketplace for the resale of our Common Stock, and we are not currently planning to list them in a formal marketplace. So long as eligibility conditions are met, the company may pursue a direct listing to the NYSE or Nasdaq.
The term Accredited Investor includes: (1) an individual who, either individually or jointly with his or her spouse, has a net worth (i.e., total assets in excess of total liabilities excluding the personal residence) of at least One Million Dollars ($1,000,000.00) or whose annual income exceeded Two Hundred Thousand Dollars ($200,000.00) in each of the last Two (2) years, or whose joint income with his or her spouse was in excess of Three Hundred Thousand Dollars ($300,000.00) in each of those years, and who has a reasonable expectation of reaching the same income level in the current year; or (2) certain institutional investors; or (3) a corporation, business, trust or partnership or trust whose investment in the Issuer is directed by a sophisticated person, in each case, not formed for the specific purpose of acquiring the Company’s Common Stocks and with total assets in excess of Five Million Dollars ($5,000,000.00); or (4) any entity in which all of the equity owners are in their own right Accredited Investors. The investor must also demonstrate: (1) that the investor, by virtue of the investor’s knowledge and experience in financial and business matters, are capable of evaluating the merits and risks of investing in the Issuer; (2) that the investor have the capacity to protect your own Common Stocks in connection with this Offering; and (3) that the investor is able to bear the risk of the Investor’s investment in the Issuer. The investor must also satisfy the Company that the investor is purchasing Common Stocks for investment only and not with a view toward resale or distribution and that the investor is an “Accredited Investor” as such term is defined in Rule 501 of Regulation D of the Securities Act.
The company intends to offer shares of Class A Common Stock at $5.00 per share. The company may at its discretion change the price of the offering.
The shares of Class A Common Stock are being offered with a minimum investment of Twenty-Five Thousand Dollars ($25,000) pursuant to Reg D506(c) and One Thousand Dollars ($1,000) pursuant to Reg A+. However, at its sole discretion, the Company may accept subscriptions for lesser amounts, reject any subscription offer, in whole or in part, for any reason or no reason.
Each prospective accredited investor participating in the offering of Shares of Class A Common Stock under Reg D506(c) will be provided with a subscription package, together with instructions, along with the Private Placement Memorandum. To subscribe for Common Shares, a subscriber must will receive a subscription package which includes the following for delivery to the company.
The company has also engaged Colonial Stock Transfer Company Inc., a registered transfer agent with the SEC, who will serve as transfer agent to maintain shareholder information on a book-entry basis.
TESTING THE WATERS LEGEND
PROMICELL IS CONSIDERING UNDERTAKING AN OFFERING OF SECURITIES UNDER TIER 2 OF REGULATION A. NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT FILED BY THE COMPANY WITH THE SEC HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND.
Disclaimer
The information provided on this website is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Investing in early-stage biotechnology companies like PromiCell involves significant risks, including the potential loss of your entire investment. Past performance does not guarantee future results, and no assurances can be made regarding the success of clinical trials, regulatory approvals, or commercialization of products. Potential investors are encouraged to consult with their financial advisors, legal counsel, and other professionals before making investment decisions. PromiCell disclaims any liability for decisions made based on the information provided herein.
Selected Risks Associated with Our Business